Entering text into the input field will update the search result below

ArQule's lead product candidate tivantinib flunks late-state liver cancer study in Japan; shares plummet 22% premarket

Mar. 27, 2017 8:07 AM ETArQule, Inc. (ARQL) StockBy: Douglas W. House, SA News Editor
  • Thinly traded nano cap ArQule (NASDAQ:ARQL) comes up empty again with lead product candidate tivantinib. A Phase 3 clinical trial, JET-HCC, in 190 Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma (HCC) previously treated with sorafenib (Bayer's Nexavar) failed to beat placebo as measured by progression-free survival (PFS).
  • Detailed results will be presented at an upcoming scientific meeting.
  • In February, tivantinib failed to beat best supportive care in a late-stage HCC study.
  • Shares are down 22% premarket on average volume.
  • Previously: ArQule's lead product candidate tivantinib flunks late-stage liver cancer study; shares down 16% (Feb. 17)

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
ARQL--
ArQule, Inc.